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Central serous retinopathy 
A B S T R A C T   
Purpose: We report the case of a 33-year-old male who presented with unilateral central serous retinopathy three 
days after the injection of a COVID-19 vaccine. 
Observations: A 33-year-old healthy Hispanic male referred to the ophthalmology service due to blurry vision and 
metamorphopsia in the right eye without any flashes, floaters, eye redness or pain. The patient reported that 69 
hours prior to presentation he received the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vac-
cine. He denied any past ocular history or pertinent medical history. He does not take any medicines and denies 
stressful factors in his life. The clinical examination and imaging tests were consistent with central serous reti-
nopathy that resolved in three months. 
Conclusions and importance: This is the first report of an ocular complication potentially associated with a COVID- 
19 vaccination. Our case contributes information of a side effect potentially related to this new vaccine.   
1. Introduction 
Since the first report of the novel coronavirus SARS-CoV-2 in China 
in December 2019, COVID-19 has been responsible for more than three 
million deaths worldwide. The ongoing outbreak of COVID-19 has been 
declared by the World Health Organization as a public health emergency 
and a vaccine to control the situation was anxiously expected. Vaccine 
development occurred in less than one year and thus, long-term data on 
side effects are still developing. 
The most common ocular manifestation of COVID-19 is hyperemia or 
conjunctival “congestion.“1,2 In addition, reports of central retinal vein 
occlusion,3 toxic shock syndrome4 and hemorrhages with microinfarcts 
have been described in COVID-19 patients.5 To the best of our knowl-
edge, no intraocular side effects have been reported from any of the 
COVID-19 vaccinations (a case of Bell’s Palsy was described in a patient 
who received the Moderna mRNA COVID-19 vaccine).6 
We present a unique case of a healthy Hispanic male who presented 
with unilateral central serous retinopathy (CSR), temporally related to 
the administration of a COVID-19 vaccine. 
2. Case report 
A 33-year-old healthy Hispanic male was referred for ophthalmo-
logical evaluation due to blurry vision and metamorphopsia in his right 
eye. He denied flashes, floaters, ocular pain or redness. He did not have 
any visual symptoms in his left eye. 
Past ocular history was negative except for mild hyperopic refractive 
error. Past medical history was only significant for hip surgery post 
traumatic injury six years prior to presentation. He denied use of any 
medications including any remote history of corticosteroids. 69 hours 
before presentation he received the Pfizer-BioNTech mRNA COVID-19 
vaccine, after which, he reported soreness at the injection site and fa-
tigue for 24 hours. Since the inception of the pandemic, the patient has 
experienced no COVID-19 symptoms and had a negative PCR result in 
November 2020. 
On exam, his best corrected visual acuity (BCVA) was 20/63 and 20/ 
25 in his right and left eye, respectively. Pupils were equally round and 
reactive to light and accommodation. Intraocular pressure was 10 
mmHg in both eyes. 
Anterior segment exam was within normal limits. Dilated fundus 
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examination was normal in the left eye but revealed loss of foveal reflex 
and swollen appearance of the macula in the right eye. No hemorrhages 
or vascular abnormalities were noted (Fig. 1A). 
Optical coherence tomography (OCT) of the right eye showed a 
macular serous detachment of the neurosensory retina (Fig. 1B) with a 
central foveal thickness (CFT) of 457 μm. OCT of the left eye was un-
remarkable. On fluorescein angiography (FA), a single point of leakage 
was noted following the classical ink-blot pattern, with progressive 
expansion of hyperfluorescence emanating from a single point (Fig. 2A). 
Consistent with previous reports of CSR,7–9 OCT angiography (OCTA) 
showed generally attenuated flow signal in the choriocapillaris that 
colocalized to the area of serous retinal detachment and foci of increased 
flow signal (Fig. 2B). 
After the initial evaluation, the patient was prescribed spi-
ronolactone 50mg daily and was evaluated two and three months later. 
At the two-month visit, BCVA improved to 20/40 and CFT decreased to 
325 μm. At the three-month visit, BCVA improved to 20/20, CFT 
decreased to 211 μm, OCT showed complete resolution of subretinal 
fluid, and the patient was asymptomatic. 
3. Discussion 
We present a case of acute unilateral CSR that developed shortly after 
immunization with the Pfizer-BioNTech mRNA COVID-19 vaccine. To 
the best of our knowledge, this is the first report of an intraocular 
complication associated with COVID-19 vaccination. 
We believe it is prudent to consider the immunization as a potential 
contributor to disease, given 1) the temporal association between im-
munization and symptom onset, 2) the relatively low incidence of CSR 
(9.9 per 100,000 individuals)10 and 3) our case’s absence of classical risk 
Fig. 1. Clinical evaluation of a patient with unilateral central serous retinopathy. Right eye (left column) and left eye (right column) are shown. Fundus photography 
of the posterior pole (A) of the right eye shows an inferotemporal parafoveal depigmented lesion. The left eye fundus was normal. Optical coherence tomography (B) 
of the right eye shows a serous detachment of the neurosensory retina in the central macula. 
Fig. 2. Vascular examinations of the effected eye of a patient with unilateral central serous retinopathy. (A) Fluorescein angiography from early (left) to late (right) 
angiogram phases show the classic expansile dot just inferotemporal to the fovea. Optical coherence tomography angiography (B) of the right eye is unremarkable in 
the superficial (left) and deep (second from left) capillary plexuses and avascular segments (second from right) but shows generally attenuated flow signal that 
colocalized to the area of serous retinal detachment and foci of increased flow signal at the level of the choriocapillaris (right). 
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factors for CSR development (including a history of exogenous steroid 
use, recent stressful social history, and type-A personality).11 While no 
cases of mRNA COVID-19 vaccine associated CSR have been reported to 
date, CSR has been associated with vaccinations against influenza, yel-
low fever, anthrax and smallpox.12–15 Still, these cases are rare. In fact, a 
search of the terms “central serous”, “central serous retinopathy”, 
“central serous chorioretinopathy” and “CSR” across all vaccine prod-
ucts by all vaccine manufacturers yielded no results from 1990 to date 
using the U.S. Centers for Disease Control and Prevention’s Vaccine 
Adverse Event Reporting System. Nevertheless, vaccines have also been 
associated with a host of chorioretinal pathologies beyond CSR. For 
example, vaccinations against influenza, yellow fever, hepatitis B, and 
Neisseria meningitidis have been associated with uveitis, acute idio-
pathic maculopathy, acute macular neuroretinopathy, 
Vogt-Koyanagi-Harada disease, and multiple evanescent white dot 
syndrome.16–23 
The pathophysiology of CSR remains incompletely understood, but 
the current literature emphasizes the role of a hyperpermeable and 
thickened choroid, as a result of hydrostatic forces, ischemia, or 
inflammation.11 Further evidence suggests endogenous and exogenous 
glucocorticoids contribute to the development of the choroidal vascul-
opathy.24 The role of retinal pigment epithelium dysfunction remains 
uncertain. Furthermore, CSR’s difficult to explain associations with 
additional risk factors—systemic hypertension,25 alcohol use,25 gastro-
esophageal reflux disease,26 and sympathomimetic agents27—offer 
additional questions about the pathophysiology of disease. 
There are several possible pathophysiologic mechanisms for the 
mRNA vaccine to cause CSR. Our hypotheses for possible pathophysio-
logic mechanisms are divided into three arms, related to increased 
serum cortisol, free extracellular mRNA, and polyethlene glycol. First, 
there is an association between CSR and high serum cortisol levels.28 
The authors could not find any data related to serum cortisol levels after 
mRNA immunizations. However in one study of a tetanus toxoid 
vaccination, serum cortisol levels increased acutely nearly two-fold after 
vaccination.29 Therefore, it seems reasonable that mRNA immunizations 
may similarly trigger endogenous glucocorticoid release. On the other 
hand, studies have consistently demonstrated that inflammatory cyto-
kines inhibit glucocorticoid receptor expression through decreased re-
ceptor translocation and binding affinity.30 Vaccines, including the 
extensively studied influenza virus vaccine, induce mild inflammatory 
responses.31–33 Another study showed that pain at injection site and 
increased body temperature were accompanied by a pro-inflammatory 
cytokine response.34 
Other potential etiologies may arise from the presence of extracel-
lular RNA. Extracellular naked RNA has been shown to increase the 
permeability of endothelial cells and may thus contribute to leaky 
choriocapillaris.35 Alternatively, extracellular naked RNA has been 
shown to promote blood coagulation and thrombus formation.36 Studies 
of CSR have highlighted that retinal areas with mid-phase inner 
choroidal staining also have delayed choroidal filling, suggesting 
choroidal lobular ischemia with associated areas of venous dilation.37,38 
Interestingly, this phenomenon may explain the attenuated flow signal 
in the choriocapillaris on OCTA in cases of CSR, including our case.7–9 
Further, elevated serum plasminogen activator inhibitor-1, a fibrino-
lytic, in CSR have led to the suggestion of a thrombotic mechanism for 
these vascular changes.39 
Finally, polyethylene glycol (PEG)-2000 is a lipid ingredient in the 
vaccine formulation meant to enable the delivery of RNA into host cells. 
PEGs are the most commonly used hydrophilic polymers used in drug 
delivery tasked to control pharmacokinetic properties and deliver drug 
to specific sites. Anaphylactic reactions have been reported in relation to 
PEG compounds, that are used in bowel preparation regimens and pre-
scription medications (e.g. methylprednisolone acetate).40 In addition, 
subretinal PEG-8 induces choroidal neovascularization and choroidal 
vessel thickening through activation of the complement pathway in 
murine models.41,42 
4. Conclusions 
Acute CSR may be temporally associated with mRNA Covid-19 
immunization. 
Patient consent 
Informed consent was obtained on this patient at the Instituto “La 
Raza,” Mexico City, Mexico. 
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